ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression

Omar Abdel-Wahab, Mazhar Adli, Lindsay M. LaFave, Jie Gao, Todd Hricik, Alan H. Shih, Suveg Pandey, Jay P. Patel, Young Rock Chung, Richard Koche, Fabiana Perna, Xinyang Zhao, Jordan E. Taylor, Christopher Y. Park, Martin Carroll, Ari Melnick, Stephen D. Nimer, Jacob D. Jaffe, Iannis Aifantis, Bradley E. Bernstein*Ross L. Levine

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

488 Scopus citations

Abstract

Recurrent somaticASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic and clinical data implicating ASXL1 mutations in myeloid malignancies, the mechanisms of transformation by ASXL1 mutations are not understood. Here, we identify that ASXL1 mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation. Through integration of microarray data with genome-wide histone modification ChIP-Seq data, we identify targets of ASXL1 repression, including the posterior HOXA cluster that is known to contribute to myeloid transformation. We demonstrate that ASXL1 associates with the PRC2, and that loss of ASXL1 in vivo collaborates with NRASG12D to promote myeloid leukemogenesis.

Original languageEnglish (US)
Pages (from-to)180-193
Number of pages14
JournalCancer cell
Volume22
Issue number2
DOIs
StatePublished - Aug 14 2012

Funding

This work was supported by a grant from the Starr Cancer Consortium to R.L.L. and B.E.B., by grants from the Gabrielle's Angel Fund to R.L.L. and O.A.-W., by a grant from the Anna Fuller Fund to R.L.L., and by an NHLBI grant to B.E.B. (5U01HL100395). I.A. and B.E.B. are Howard Hughes Medical Institute Early Career Scientists. A.M. is a Burroughs Wellcome Clinical Translational Scholar and Scholar of the Leukemia and Lymphoma Society. X.Z. and S.D.N. are supported by a Leukemia and Lymphoma Society SCOR award, and F.P. is supported by an American Italian Cancer Foundation award. O.A.-W. is an American Society of Hematology Basic Research Fellow and is supported by a grant from the NIH K08 Clinical Investigator Award (1K08CA160647-01). J.P.P. is supported by an American Society of Hematology Trainee Research Award.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression'. Together they form a unique fingerprint.

Cite this